Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam

Overview

The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection. RBT represents an alternative to RMP for HIV infected patients as its half-life is longer and the enzymatic induction effect appears to be less important on the associated antiretroviral therapy (ART) drugs. This phase II trial is to determine precisely the pharmacokinetics parameters of RBT in combination with different ART regimens in Vietnamese HIV infected patients with pulmonary tuberculosis, in order to define optimal doses that will be further tested in a larger phase III trial comparing safety, tolerability and efficacy of RBT and RMP regimens.

Full Title of Study: “Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in Vietnam : A Phase II Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2012

Detailed Description

Patients will be offered to participated in the study when they start TB treatment. All the enrolled patients will immediately be switched to rifabutin and randomized, to one of the RBT doses that will be then adapted to the allocated RBT regimen according to a cross over scheme. Three full pharmacokinetics profile will be performed at different time point : before initiation of ARV, after three weeks of the first RBT dosage and after three weeks of the secondRBT dosage. Patients will then be referred to the national program for further treatment. A follow-up visit will be planned at the end of the antiTB treatment.

Interventions

  • Drug: rifabutin in combination with lopinavir boosted by ritonavir – dosing schedule 1
    • 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
  • Drug: rifabutin in combination with lopinavir boosted by ritonavir – dosing schedule 2
    • 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);

Arms, Groups and Cohorts

  • Experimental: 1
    • RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
  • Experimental: 2
    • RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART

Clinical Trial Outcome Measures

Primary Measures

  • Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with lopinavir/ritonavir)
    • Time Frame: 2, 5 and 8 weeks after randomisation

Secondary Measures

  • Area under the curve (AUC) of lopinavir/ritonavir in combination with two doses of rifabutine
    • Time Frame: 5 and 8 weeks after randomisation
  • Safety : proportion of patients with grade 3 and grade 4 adverse events
    • Time Frame: through out the trial

Participating in This Clinical Trial

Inclusion Criteria

  • Pulmonary tuberculosis defined as either – at least 2 sputum smears positive for AFB – 1 sputum smear positive for AFB and a chest radiograph compatible with active tuberculosis – 1 sputum culture positive and and a chest radiograph compatible with active tuberculosis – a clinical history and chest radiograph compatible with active tuberculosis and 2 sputum smear negative for AFB – Positive HIV antibody and CD4 count <=250 /mm3 – Weight > 40 kg – No history of ART – No grade 3 or 4 clinical or laboratory findings – Negative pregnancy test and appropriate contraceptive measures during the duration of the trial for female of childbearing age – Having a firm home address that is readily accessible – Karnofsky score>=80% Exclusion Criteria:

  • History of TB or MDR TB treatment – Concomitant OI requiring additional anti-infectious treatment – Formal contraindication to any drug used in the trial – Diabetes mellitus requiring drug treatment – Recreational drug or alcohol abuse – History of drug hypersensitivity to TB or related medications – Interrupted TB therapy for more than 1 week – Less than 90% adherent to first 6 weeks of intensive phase chemotherapy – Mental illness that could impair ability to give informed consent or result in poor adherence to trial protocol and therapy – Neutropenia <1200 /L, anaemia <6.8 g/dL, liver function test > grade 2 – Requiring concomitant medications that may potentially interact with study drugs – Pregnant or lactating women – Karnofsky score >80% – Any condition rendering the patient unable to understand the nature, scope, and possible consequences of thes study and to provide consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • French National Agency for Research on AIDS and Viral Hepatitis
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Anthony D. Harries, PhD, Principal Investigator, The international Union Against Tuberculosis and Lung Diseases (IUATLD), Paris, France
    • Huy Dung Nguyen, MD, Principal Investigator, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.